No class-action suit over Vioxx, judge rules

Share this article:
A federal judge denied a request by users of Merck’s withdrawn painkiller Vioxx to pool thousands of personal injury cases into a single class-action lawsuit. The order, issued by US District Judge Eldon Fallon, means that Vioxx users who claim they were injured by the drug must sue only on their own behalf. Fallon did not rule on the possibility of separate class-actions suits for each state and the District of Columbia, though. Plaintiffs had proposed trying all of the cases under the laws in New Jersey, arguing that Merck should reasonably expect to follow the laws of the state where it is headquartered. Fallon ruled that it makes more sense to apply the law of each plaintiff's home state to that plaintiff's claims. In addition, although he wrote that he was "confident that common questions exist" among the more than 7,000 remaining cases, plaintiff allegations of Merck’s negligence in failing to warn doctors about Vioxx "necessarily turn on numerous individualized issues." Merck had vowed to fight each Vioxx case individually.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.